Disc Medicine posts smaller-than-expected Q2 net loss
Disc Medicine posts smaller-than-expected Q2 net loss
Overview
US biopharma firm's Q2 net loss and operating income both beat analyst expectations
Q2 loss per share was better than expected
Operating expenses rose yr/yr due to pipeline advancement and higher headcount
Outlook
Disc Medicine expects APOLLO Phase 3 topline results in Q4 2026
Company anticipates submitting CRL response and receiving FDA decision by mid-2027
Result Drivers
PIPELINE ADVANCEMENT - Co said higher R&D expenses were driven by advancement of selcodebart and DISC-3405 clinical studies and drug manufacturing
HEADCOUNT INCREASE - Co said higher SG&A and R&D expenses were partly due to increased headcount
BITOPERTIN MANUFACTURING COSTS - Decrease in bitopertin manufacturing costs partially offset R&D expense increases
Company press release: ID:nGNX4XH3s8
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Loss | Beat | $59.53 mln | $68.24 mln (9 Analysts) |
Q2 Loss Per Basic Share | Beat | $1.54 | $1.75 (10 Analysts) |
Q2 Operating Income | Beat | -$65.08 mln | -$71.04 mln (10 Analysts) |
Q2 Operating Expenses |
| $65.08 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Disc Medicine Inc is $100.00, about 35.7% above its July 29 closing price of $73.67
Reuters Recommended Reads
July 30 - Crescent Biopharma posts smaller-than-expected Q2 net loss
July 30 - Anavex Life Sciences Q2 net loss narrows on lower R&D costs
July 29 - Corcept Therapeutics Q2 revenue estimates, raises 2026 outlook
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)